Formycon AG (FRA:FYB)
25.10
+0.10 (0.40%)
Last updated: Aug 15, 2025
Formycon AG Revenue
Formycon AG had revenue of 42.78M EUR in the half year ending December 31, 2024, with 72.14% growth. This brings the company's revenue in the last twelve months to 51.78M, down -14.84% year-over-year. In the year 2024, Formycon AG had annual revenue of 69.67M, down -10.32%.
Revenue (ttm)
51.78M
Revenue Growth
-14.84%
P/S Ratio
8.53
Revenue / Employee
207.11K
Employees
250
Market Cap
441.42M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 69.67M | -8.02M | -10.32% |
Dec 31, 2023 | 77.70M | 35.20M | 82.83% |
Dec 31, 2022 | 42.50M | 5.88M | 16.07% |
Dec 31, 2021 | 36.61M | 2.32M | 6.76% |
Dec 31, 2020 | 34.30M | 1.14M | 3.43% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SAP SE | 35.89B |
Siemens Aktiengesellschaft | 78.30B |
Deutsche Telekom AG | 120.55B |
Allianz SE | 109.02B |
Siemens Energy AG | 38.39B |
Rheinmetall AG | 10.67B |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.33B |
Deutsche Bank Aktiengesellschaft | 30.07B |
Formycon AG News
- 17 days ago - EQS-News: Formycon invites to conference call on 2025 half-year results and announces participation in international investor conferences in the 3rd quarter of 2025 - Wallstreet:Online
- 4 weeks ago - EQS-AFR: Formycon AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] - Wallstreet:Online
- 5 weeks ago - EQS-News: Formycon successfully completes patient enrollment for the clinical development of its Keytruda biosimilar candidate FYB206 - Wallstreet:Online
- 6 weeks ago - EQS-News: Bio Usawa becomes partner for the commercialization of FYB201/ BioUcenta (ranibizumab) across Sub-Saharan Africa - Wallstreet:Online
- 7 weeks ago - EQS-Adhoc: Formycon successfully places an EUR 70 million senior unsecured floating rate bond - Wallstreet:Online
- 7 weeks ago - EQS-News: Teva becomes secondary commercialization partner for Formycon's Stelara biosimilar FYB202 (ustekinumab) under the brand name Fymskina in Germany - Wallstreet:Online
- 7 weeks ago - EQS-News: U.S. biosimilar specialist Valorum Biologics LLC becomes commercialization partner for Formycon’s Eylea biosimilar FYB203/AHZANTIVE (aflibercept-mrbb) in the United States and Canada - Wallstreet:Online
- 7 weeks ago - EQS-News: Strong demand for Formycon 2025/2029 Bond leads to early closing of subscription period - Wallstreet:Online